Longitudinal | TB clinics, MCI and JGH, Canada | 105 | 48 | 110 | June 2008–October 2011 (40 months) | 1) SF-36 → SF-6D utilities 2) SG | HRQoL [19] Health utilities [18] | [18, 19] |
Prospective cohort | Broward or Palm Beach County Health Dept, Florida, USA | 90 | | | August 2005–July 2007 (24 months) | 1) Stigma scale from EMIC for Tuberculosis in Haitian Populations | Stigma | [20] |
Cross-sectional | TB clinic, MCI, Canada | 35 | 22 | | 1 September 1999–30 September 2000 (13 months) | 1) VAS 2) SG 3) SF-36 4) EQ-5D | HRQoL | [21, 22] |
Qualitative | TB-OPD, Karolinska University Hospital, Solna, Sweden | 16 | | | December 2017–June 2018 (7 months) | Interview guide | Treatment experience | [23] |
Longitudinal | TB clinic, British Columbia Centre for Disease Control, Canada | 102 | 104 | | 2005–2006 (12 months) | 1) SF-36 v2→SF-6D utilities 2) BDI 3) HUI2, HUI3 4) VAS | HRQoL [24] Health utilities [25] | [24, 25] |
Retrospective | TB registries, 20 different sites in the USA | 7 282 | 3853 | | 1993–31 December 2002 (9 years) | 1) Mortality risk | Mortality | [26] |
Retrospective | TB clinic, TCPH, Texas, USA | 210 | 107 | | 7 July 2005–7 November 2006 (16 months) | 1) SGRQ | HRQoL [27] QALY [22] | [27, 28] |
Cross-sectional | Infectious disease or paediatric clinics, Karolinska University Hospital, Sweden | 108 | | 19 415 | September 2017–June 2018 (10 months) | 1) EQ-5D 2) RHS-15 | HRQoL | [29] |
Cross-sectional | Dispensary of TB Kayseri, Turkey | 108 | 196 | 196 | 15 September 2003–15 September 2004 (12 months) | 1) SF-36 2) BDI | HRQoL | [30] |